Announcement

28.03.2011


Pursuant to Articles 9 and 10 of the Articles of Association, notice is hereby
given of the Annual General Meeting to be held on:

Wednesday, 27 April 2011 at 4.00 pm

at the Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9,
DK-2000 Frederiksberg, Copenhagen.

The agenda and complete proposals can be seen from the enclosed PDF file.


Thomas Hofman-Bang
Chairman of the Board of Directors



Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097

About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique
orphan drug in Phase III for the treatment of Huntington's disease. NeuroSearch
is building commercial competences with a view to commercialising Huntexil®
through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and CNS diseases. The company
has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of unlisted companies in the
Life Science industry.

Fonds.08-11 - Notice convening Annual General Meeting - UK.pdf